Form 4: Xenon Pharmaceuticals Director Acquires Stock Options

Patrick Machado, a director at Xenon Pharmaceuticals, acquired stock options for 15,542 common shares on June 5, 2024, according to a recent SEC filing.

Summary

• On June 5, 2024, Patrick Machado, a director of Xenon Pharmaceuticals Inc., acquired stock options for 15,542 common shares.
• The exercise price of these options is $38.16.
• The options vest on the earlier of June 4, 2025, or the day before the company's 2025 annual meeting of shareholders.
• The options expire on June 4, 2034.
• This transaction was reported on a Form 4 filed with the SEC.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard transaction (stock option grant) for a company director. It doesn't inherently indicate positive or negative sentiment, but rather a routine part of executive compensation.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance beyond the vesting and expiration dates of the options.

Industry Context

This type of transaction is common for directors and officers of publicly traded companies as part of their compensation packages and to align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry, used to incentivize performance and align management interests with shareholder value.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their executive compensation plans.
• The vesting schedules and exercise prices are generally benchmarked against industry peers to ensure competitiveness and effectiveness in retaining key personnel.

Stakeholder Impact

• The granting of stock options to a director can potentially align the director's interests with those of the shareholders, as the value of the options is tied to the company's stock performance.

Key Dates